Pertaining to platelet activation, the PCSK9-REACT study (Association of PCSK9 Serum levels and Platelet Reactivity in Patients with Acute Coronary Syndrome Treated with Prasugrel or Ticagrelor), performed on consecutive ACS patients undergoing percutaneous coronary intervention with a mean age of 57 years, found a positive association between circulating PCSK9 and platelet reactivity in patients with ACS undergoing percutaneous coronary intervention (42). The gene discussed is PCSK9; the disease is acute coronary syndrome.